Ryo Okuda

Dr. Ryo Okuda

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2013 in Respiratory Medicine
Verified
Journal Article
Closed access
RORyo Okuda
Ryo Okuda
EHEri Hagiwara
Eri Hagiwara
TBTomohisa Baba
Tomohisa Baba
HKHideya Kitamura
Hideya Kitamura
TKTerufumi Kato
Terufumi Kato
TOTakashi Ogura
Takashi Ogura

1 March 2019 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
RORyo Okuda
Ryo Okuda
KAKazutetsu Aoshiba
Kazutetsu Aoshiba
HMHidekazu Matsushima
Hidekazu Matsushima
TOTakashi Ogura
Takashi Ogura
KOKoji Okudela
Koji Okudela
KOKenichi Ohashi
Kenichi Ohashi
Background: The senescence-associated secretory phenotype (SASP) develops due to cellular senescence during conditions such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). However, studies comparing the degree of cellular senescence and SASP between COPD and IPF are limited. Furthermore, to the best of our knowledge, no study has examined cellular senescence and/or SASP in connective tissue disease-associated interstitial lung disease (CTD-ILD). Methods: To compare the degree of cellular senescence among COPD, IPF, and CTD-ILD, tissue samples from surgical lung biopsies or noncancerous tissue from lobectomy specimens of patients with lung cancer were subjected to immunostaining for p16 and p21. Double-staining for p16 and phosphorylated NF-κB was performed to verify the relationship between cellular senescence and SASP. Results: There was a greater degree of enhancement of p16 and p21 expression in patients with IPF than in those with COPD and controls. Immunostaining for p16 revealed an enhanced expression of this marker in patients with COPD compared with that in controls. No significant differences were observed in the phosphorylated NF-κB expression rate of p16-positive and p16-negative cells among patients with IPF, CTD-ILD, and COPD. Conclusions: Epithelial cells in patients with IPF express higher levels of both cellular senescence and SASP than those in patients with COPD or controls.

31 October 2015 in SpringerPlus
Verified
Journal Article
Open access
PDF file
RORyo Okuda
Ryo Okuda
HMHidekazu Matsushima
Hidekazu Matsushima
KAKazutetsu Aoshiba
Kazutetsu Aoshiba
TOTomohiro Oba
Tomohiro Oba
RKRie Kawabe
Rie Kawabe
MAMasako Amano
Masako Amano
The levels of soluble intercellular adhesion molecule-1 (sICAM-1) have been reported to increase in patients with idiopathic pulmonary fibrosis. However, the utility of sICAM-1 has not been reported in detail. The aim of this study was to investigate whether sICAM-1 was a useful biomarker for stable idiopathic pulmonary fibrosis (IPF) and early phase of acute exacerbation of IPF. The patients who were diagnosed with IPF between 2013 and 2015 were enrolled. The levels of sICAM-1 and other interstitial pneumonia markers were measured. In this study, 30 patients with stable IPF and 11 patients with acute exacerbation of IPF were collected. Mean sICAM-1 levels were 434 ± 139 ng/mL for the stable phase of IPF, 645 ± 247 ng/mL for early phase of acute exacerbation of IPF, 534 ± 223 ng/mL for connective tissue disease-associated interstitial pneumonia, 221 ± 42 for chronic obstructive pulmonary disease, and 150 ± 32 ng/mL in healthy volunteers. For the stable phase of IPF, sICAM-1 levels correlated with Krebs von den Lungen-6 (KL-6) (r value: 0.41; p value: 0.036). Mean sICAM-1 levels were significantly higher in patients with early phase of acute exacerbation of IPF than with stable phase of IPF (p = 0.0199). Multiple logistic analyses indicated that the predictors for early phase of acute exacerbation of IPF were only sICAM-1 and C-reactive protein (odds ratio: 1.0093; 1.6069). In patients with stable IPF, sICAM-1 levels correlated with KL-6; sICAM-1 might be a predictive indicator for prognosis. In the early phase of acute exacerbation of IPF, sICAM-1 might be more useful for diagnosis than other interstitial pneumonia markers.


24 August 2023 in Respiration
Verified
Journal Article
Closed access
PDF file
RORyo Okuda
Ryo Okuda
TTTamiko Takemura
Tamiko Takemura
TMToshihiro Misumi
Toshihiro Misumi
RNRyo Nagasawa
Ryo Nagasawa
TITae Iwasawa
Tae Iwasawa
TOTakashi Ogura
Takashi Ogura
Background: Acute exacerbation (AE) occasionally develops in the course of fibrotic hypersensitivity pneumonitis (HP). Objective: The aim of the study was to compare AE of fibrotic HP with that of idiopathic pulmonary fibrosis (IPF). Methods: Consecutive patients with pathologically confirmed fibrotic HP and IPF diagnosed based on a multidisciplinary discussion were included in the analysis. AE in patients with fibrotic HP and IPF was evaluated retrospectively. Results: This study included 309 and 160 patients with fibrotic HP and IPF, respectively. Their 50% survival times were 96.1 and 78.0 months, respectively (hazard ratio [HR]: 0.54 [95% confidence interval, CI: 0.36–0.77], log-rank test; p < 0.001). Notably, the cumulative AE rates of fibrotic HP were 3% at 1 year and 10% at 3 years. Moreover, the corresponding rates of IPF were 8% at 1 year and 20% at 3 years (HR: 0.66 [95% CI: 0.45–0.93], log-rank test; p = 0.034). The 90-day survival rates from the AE onset of fibrotic HP and IPF were 75% and 64%, respectively (HR: 0.51 [95% CI: 0.31–0.83], log-rank test; p = 0.006). The respiratory function test on the physiological criteria of progressive pulmonary fibrosis (PPF) was a predictor of AE in fibrotic HP. However, the high-resolution CT (HRCT) changes in the criteria of PPF were not. Nevertheless, both the physiological and radiological criteria of PPF were a predictor of AE of IPF. Conclusion: AE of fibrotic HP has a lesser prognostic effect than that of IPF. HRCT criteria for PPF were not a risk factor for AE in patients with fibrotic HP.

16 December 2015 in Respiratory Investigation
Verified
Journal Article
Closed access
PDF file
RORyo Okuda
Ryo Okuda
HMHidekazu Matsushima
Hidekazu Matsushima
TOTomohiro Oba
Tomohiro Oba
RKRie Kawabe
Rie Kawabe
MMMinako Matsubayashi
Minako Matsubayashi
KHKoujiro Honda
Koujiro Honda